No abstract available.
Diagnosis* ; Prostate* ; Prostatic Neoplasms* ; Ultrasonography*

No abstract available.
Lithotripsy* ; Shock* ; Ureter* ; Ureteroscopy*

No abstract available.

No abstract available.
Hernia*

Patients with advanced urothelial tumors that relapse or persist following conventional therapy have poor prognosis. Management of the patients with recurrent local or disseminated urothelial tumors presents a difficult clinical problems. In 1985 Sternberg et al reported 71% of significant tumor regression and 50% of complete clinical remission with M-VAC (methotrexate, vinblastine, doxorubicin and Cisplatin) combination chemotherapy for treatment of advanced urothelial transitional cell carcinomas. Herein, we have experienced 13 cases of M-VAC combination chemotherapy in advanced urothelial tumors. Complete and partial remission was in achieved 46.2 per cent of the patients clinically, while 15.4 percent had a minor response and 38.4 per cent had progression with median survivals of 11.5, 8.5 and 7.4 months. Toxicity was significant. 15.4 per cent of the patients having experienced nadir sepsis, 30.8 per cent mucositis and 7.6 per cent cardiac toxicity. Median cycle length varied from 31.6 to 41.7 days for the first and 5th cycle respectively. This regimen has been efficacious in selected patients with advanced urothelial tumors.
Carcinoma, Transitional Cell ; Doxorubicin* ; Drug Therapy, Combination ; Humans ; Mucositis ; Prognosis ; Recurrence ; Sepsis ; Vinblastine*

No abstract available.
Urinary Bladder Neoplasms* ; Urinary Bladder*

Wilms` tumor originates from pleuripotential mesenchymal cells of the metanephrogenic blastema. Improvement on surgery and anesthesia, addition of radiation therapy and chemotherapy have produced remarkable improvements in survival over the past several decades. Twenty-eight patients with histologically confirmed diagnoses of Wilms` tumor were treated from l972 through l987 at the University Hospital, Keimyung University School of Medicine. l. Two year survival rate according to tumor stage was 80% in stage I, 7516 in stage II , 57.1% in stage III and 25% in stage IV and the overall 2 year survival rate was 57.1 1K . 2. Two year survival rate according to age was 75% in below l year, 50% between l to 2 years old, 54.5% between 2 to 6 years old and 60% above 6 years old. However, there seems to be no close relationship between age and prognosis. 3. Two year survival rate before 1978 was 45.5% and after 1978 was 45.5% and after 1978 it was 61.6% 4. There was 76.0 percent overall survival for those with negative nodes versus 33.3 per cent survival for those with positive nodes. 5. Two year survival rates of FH(Favorable Histology) and UH(Unfavorable Histology) were 68.2% and 16.7% respectively. There seems to be close relationship between FH and UH.
Anesthesia ; Child ; Child, Preschool ; Diagnosis ; Drug Therapy ; Humans ; Prognosis* ; Survival Rate

No abstract available.
Diagnosis* ; Ultrasonography* ; Varicocele*

In adenomatous polyposis coli there are many colonic and extracolonic manifestations, and various combinations of these induce different clinical presentations and syndromes. We experienced a unique case of adenomatous polyposis of the large intestine and stomach in a 39-year-old man. In the colon, small cell neuroendocrine carcinoma rather than adenocarcinoma had developed, which did not contain adenomatous or carcinomatous foci. The adenomatous polyps in the colon were all small and sessile with no cancerous or precancerous change two years after the resection of the symptomatic gastric adenomas, even though the gastric adenomas were larger and showed dysplastic change. We think this case is another variant of adenomatous polyposis syndrome.
Adenocarcinoma ; Adenoma

Prostatitis is a prevalent condition that encompasses a large array of clinical symptoms with significant impacts on men's life. The diagnosis and treatment of this disorder presents numerous challenges for urologists, most notably, a lack of specific and effective diagnostic methods. Chronic bacterial prostatitis is successfully treated with appropriate antibiotics that penetrate the prostate and kill the causative organisms. Prostatitis category III (chronic pelvic pain syndrome) is common, very bothersome, and enigmatic. Symptoms are usually prolonged and, generally speaking, treatment results are unsatisfactory. During the last decade, research has focused on the distress caused by the condition, but although our knowledge has certainly increased, there have been no real breakthroughs; controversies and many unanswered questions remain. Furthermore, the optimal management of category III prostatitis is not known. Conventional prolonged courses of antibiotic therapy have not proven to be efficacious. Novel therapies providing some evidence for efficacy include alpha-blocker, anti-inflammatory phytotherapy, physiotherapy, neuroleptics, and others, each offering therapeutic mechanisms. A stepwise approach involving multimodal therapy is often successful for treating patients. The UPOINT technique has been used to clinically phenotype these patients and drive the appropriate selection of multimodal therapy.
Anti-Bacterial Agents ; Antipsychotic Agents ; Humans ; Pelvic Pain ; Phenotype ; Phytotherapy ; Prostate ; Prostatitis